IBJNews

Potential competitor to Lilly drug shows promise in study

Back to TopCommentsE-mailPrintBookmark and Share

Sanofi-Aventis SA’s experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s twice-daily medicine Byetta in keeping blood-sugar levels in check, a study found.

The advanced study of 639 patients with the most common form of diabetes, known as Type 2, showed those taking the Sanofi drug also had fewer instances of hypoglycemia, a state of dangerously low blood sugar, Paris-based Sanofi said in a statement.

The findings could lead to more competition for Indianapolis-based Lilly, which markets Byetta outside the United States and co-markets it with Amylin in the U.S. The drug had worldwide sales of $796.5 million in 2009.

Diabetes occurs when the body doesn’t produce or properly use insulin, a hormone needed to convert sugar, starches and other food into the energy needed for daily life. Lixisenatide belongs to a class of drugs that imitate a hormone called GLP-1 to stimulate the pancreas to produce more insulin after meals. Both lixisenatide and Byetta are injections.

Sanofi trails Novo Nordisk A/S and Lilly in developing a GLP-1 product. Peter Welford, an analyst at Jefferies International Ltd., wrote in a note to investors Tuesday that he expects lixisenatide to have "blockbuster" sales. The full study will be released at a medical conference, the drugmaker said. Zealand Pharma A/S of Denmark developed lixisenatide from the spit of the Gila monster.

Byetta uses a synthetic version of a substance in Gila monster saliva.

Separately, Roche Holding AG said Tuesday that it’s stopping development of another GLP-1 treatment, taspoglutide, and returning rights to developer Ipsen SA.

After “extensive analysis,” the Switzerland-based company said it has decided to stop development of the medicine. Ipsen said it will sift through the Roche research and could seek another partner. The decision may mean the end of development for a drug that some analysts once predicted would have annual sales of more than $1.38 billion and compete with Byetta and Novo Nordisk’s Victoza.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. With Pence running the ship good luck with a new government building on the site. He does everything on the cheap except unnecessary roads line a new beltway( like we need that). Things like state of the art office buildings and light rail will never be seen as an asset to these types. They don't get that these are the things that help a city prosper.

  2. Does the $100,000,000,000 include salaries for members of Congress?

  3. "But that doesn't change how the piece plays to most of the people who will see it." If it stands out so little during the day as you seem to suggest maybe most of the people who actually see it will be those present when it is dark enough to experience its full effects.

  4. That's the mentality of most retail marketers. In this case Leo was asked to build the brand. HHG then had a bad sales quarter and rather than stay the course, now want to go back to the schlock that Zimmerman provides (at a considerable cut in price.) And while HHG salesmen are, by far, the pushiest salesmen I have ever experienced, I believe they are NOT paid on commission. But that doesn't mean they aren't trained to be aggressive.

  5. The reason HHG's sales team hits you from the moment you walk through the door is the same reason car salesmen do the same thing: Commission. HHG's folks are paid by commission they and need to hit sales targets or get cut, while BB does not. The sales figures are aggressive, so turnover rate is high. Electronics are the largest commission earners along with non-needed warranties, service plans etc, known in the industry as 'cheese'. The wholesale base price is listed on the cryptic price tag in the string of numbers near the bar code. Know how to decipher it and you get things at cost, with little to no commission to the sales persons. Whether or not this is fair, is more of a moral question than a financial one.

ADVERTISEMENT